Injectable dual thermoreversible hydrogel for sustained intramuscular drug delivery

Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2024-10, Vol.374, p.590-605
Hauptverfasser: Din, Fakhar Ud, Kim, Jung Suk, Lee, Ho Cheol, Cheon, Seunghyun, Woo, Mi Ran, Woo, Sanghyun, Ku, Sae Kwang, Yoo, Hye Hyun, Kim, Jong Oh, Jin, Sung Giu, Choi, Han-Gon
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Herein, we reported novel docetaxel-decorated solid lipid nanoparticle (DCT-SLN)-loaded dual thermoreversible system (DCT-DRTS) for intramuscular administration with reduced burst effect, sustained release and improved antitumor efficacy. The optimized DCT-DRTs was subjected to in-vitro and in-vivo analyses. Antitumor evaluation of the DCT-DRTS was executed and compared with DCT-hydrogel, and DCT-suspension trailed by the histopathological and immune-histochemical analyses. The DCT-SLN gave a mean particle size of 157 nm and entrapment efficiency of 93 %. It was a solid at room temperature, and changed to liquid at physiological temperature due to its melting point of about 32 °C. Unlikely, poloxamer mixture remained liquefied at 25-27 °C, however converted to gel at physiological temperature. This behavior demonstrated opposed reversible property of the DCT-SLN and poloxamer hydrogel in DCT-DRTS system, making it ideal for intramuscular administration and quick gelation inside the body. The DCT-DRTS sustained the drugs release and unlike DCT-hydrogel, the preliminary plasma concentration of DCT-DRTS was significantly reduced, overcoming the burst release. A meaningfully enhanced antitumor efficacy and improved survival rate was observed from DCT-DRTS in tumor cell xenograft athymic nude mice. Additionally, increased apoptotic and reduced proliferation markers were observed in DCT-DRTS treated tumor masses. It was concluded that DCT-DRTS may be a suitable choice for intramuscular administration of DCT with sustained release, improved bioavailability, reduced toxicity and enhanced antitumor effects. [Display omitted] •Docetaxel (DCT), has been used extensively for the treatment of various cancers.•We developed a novel sustained release formulation DCT-DRTS for intramuscular route.•DCT-DRTS was composed of thermosensitive solid lipid nanoparticle and hydrogel.•It demonstrated improved bioavailability, no toxicity and greater antitumor effects.•High apoptosis and reduced proliferation of tumor masses were observed in DCT-DRTS.
ISSN:0168-3659
1873-4995
1873-4995
DOI:10.1016/j.jconrel.2024.08.034